title: Linker technologies for antibody-drug conjugates.
abstract: Antibody-drug conjugates (ADCs), which combine the specificity, favorable pharmacokinetics, and biodistribution of a monoclonal antibody (mAb) with the cytotoxic potency of a drug, are promising new therapies for cancer. Along with the development of monoclonal antibodies (mAbs) and cytotoxic drugs, the design of the linker is of essential importance, because it impacts the efficacy and tolerability of ADCs. The linker needs to provide sufficient stability during systemic circulation but allow for the rapid and efficient release of the cytotoxic drug in an active form inside the tumor cells. This review provides an overview of linker technologies currently used for ADCs and advances that have resulted in linkers with improved properties. Also provided is a brief summary of some considerations for the conjugation of antibody and drug linker such as drug-to-antibody ratio and site of conjugation.
authors.affiliation: Biotherapeutics Research and Development, Pfizer, Pearl River, NY, USA.
authors.forename: Birte
authors.initials: B
authors.lastname: Nolting
mesh_terms: D000818:Animals; D004220:Disulfides / Q000737:chemistry; D020719:Glucuronides / Q000737:chemistry; D006801:Humans; D006835:Hydrazones / Q000737:chemistry; D018796:Immunoconjugates / Q000737:chemistry*; D010455:Peptides / Q000737:chemistry; D004364:Pharmaceutical Preparations / Q000737:chemistry*
chemical_list: D004220:Disulfides; D020719:Glucuronides; D006835:Hydrazones; D018796:Immunoconjugates; D010455:Peptides; D004364:Pharmaceutical Preparations